Skip to content
value.today

Equillium, Inc.

EQ
$103 Mmarket cap on Oct 27, 2026+281.1% since Jan 2024
Compare
World rank
#18,632
Revenue
—
For year ending December-2025
Net income
$-22 M
SEC filing
Employees
14
As of December 31, 2025
SEC filing

Equillium, Inc. in brief

Equillium, Inc. is a listed company in the Biotechnology industry, based in La Jolla, California, USA. Its market value was $103 M on 27 October 2026, which makes it the 18,632nd largest listed company in the world and the 3,505th largest in the USA on this site. It employs about 14 people and Bruce D. Steel is its chief executive. Its shares trade under the symbol EQ (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Equillium, Inc.

We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development.

EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial impact inducing anti-inflammatory cells and cytokines while reducing proinflammatory cells and cytokines and improving intestinal tissue barrier function and repair. We initially intend to develop EQ504 for the treatment of ulcerative colitis, or UC, and other gastrointestinal, or GI, diseases with potential indication expansion opportunities for the treatment of inflammatory lung diseases.

From the company's annual report filed with the US SEC: read the report

Equillium, Inc. timeline

3 events, 2018–2024
  1. 2018
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 12 October 2018; shares registered for exchange trading on 5 October 2018.
  4. 2024
  5. 💰
    Record revenue of $41 million
    FY2024, the highest of the 3 years on record.

Events of Equillium, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$40 M$80 M$121 M$161 M2020202120222023202420252026

World rank over time

▲ up 1,872 places since 2020
2020-01-01: #20551#20,55120202021-01-01: #17141#17,14120212022-01-07: #22696#22,69620222022-12-25: #27437#27,43720222023-07-30: #28464#28,46420232024-01-05: #27660#27,66020242026-03-08: #9867#9,86720262026-08-01: #16222#16,22220262026-10-07: #18258#18,25820262026-10-27: #18679#18,6792026

Rank in USA: #3,943 (Jan 2020) · #3,517 (Jan 2021) · #4,398 (Jan 2022) · #5,066 (Dec 2022) · #5,093 (Jul 2023) · #4,291 (Jan 2024) · #1,920 (Mar 2026) · #3,244 (Aug 2026) · #3,413 (Oct 2026) · #3,509 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.6×
Free cash flow yield
-22.2%
Net margin
—
Operating margin
—
Return on equity
-78.3%
Liabilities / assets
10.3%
Net debt
$-50M
Revenue growth
+13.9%
R&D / revenue
91.1%
Profit per employee
$-1.6 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-13M—FY18Fiscal year ending Dec 2019: revenue —, net income $-26M—FY19Fiscal year ending Dec 2020: revenue —, net income $-30M—FY20Fiscal year ending Dec 2021: revenue —, net income $-39M—FY21Fiscal year ending Dec 2022: revenue $16M, net income $-62M$16MFY22Fiscal year ending Dec 2023: revenue $36M, net income $-13M$36MFY23Fiscal year ending Dec 2024: revenue $41M, net income $-8M$41MFY24Fiscal year ending Dec 2025: revenue —, net income $-22M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-24M$-22M—
Dec 2024$41M+13.9%$-8M$-8M-19.6%
Dec 2023$36M+128.9%$-15M$-13M-37.0%
Dec 2022$16M—$-62M$-62M-396.1%
Dec 2021——$-38M$-39M—
Dec 2020——$-30M$-30M—
Dec 2019——$-27M$-26M—
Dec 2018——$-9M$-13M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-23M$0M$-23M$-0.39—
Dec 2024$-19M$0M$-19M$-0.23—
Dec 2023$-22M$0M$-22M$-0.38—
Dec 2022$-9M$0M$-9M$-1.85—
Dec 2021$-32M$0M$-32M$-1.36—
Dec 2020$-25M$0M$-25M$-1.46—
Dec 2019$-23M$0M$-23M$-1.47—
Dec 2018$-8M$0M$-8M$-1.09—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $4M, net income $-6M$4MDec ’24Three months to Mar 2025: revenue —, net income $-9M—Mar ’25Three months to Jun 2025: revenue —, net income $-6M—Jun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-4M—Dec ’25Three months to Mar 2026: revenue —, net income $-5M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-5M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Equillium, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-24 M
Net income
$-22 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$32 M
Total liabilities
$3 M
Total equity
$29 M

As of December-2025

Top 66 institutional investors in Equillium, Inc.#

As of Sep 30, 2026
66 institutions held 40.9 M shares (about 49.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 40.3%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Equillium, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.6,494,571—7.89%$11 MNov 16, 2026
2Aberdeen Group plc4,458,351+826,692 (+22.76%)5.42%$7 MNov 10, 2026
3Decheng Capital LLC4,447,3080 (0.00%)5.40%$7 MNov 13, 2026
4Woodline Partners LP3,500,9010 (0.00%)4.25%$6 MNov 16, 2026
5ADAR1 Capital Management, LLC3,446,539-312,030 (-8.30%)4.19%$6 MNov 16, 2026
6Affinity Asset Advisors, LLC2,613,954-1,486,046 (-36.25%)3.18%$4 MNov 13, 2026
7Bank Of America Corp /de/2,600,032New3.16%$4 MNov 16, 2026
8Ra Capital Management, L.P.2,317,741-778,595 (-25.15%)2.82%$4 MNov 16, 2026
9Vanguard Capital Management LLC2,013,744+190,932 (+10.47%)2.45%$3 MNov 13, 2026
10Eversept Partners, LP1,294,446-226,378 (-14.89%)1.57%$2 MNov 16, 2026
11Marshall Wace, LLP750,188New0.91%$1 MNov 13, 2026
12Citadel Advisors LLC592,417+492,755 (+494.43%)0.72%$1 MNov 16, 2026
13Exome Asset Management LLC552,9560 (0.00%)0.67%$1 MNov 16, 2026
14Adage Capital Partners GP, L.L.C.524,403-865,850 (-62.28%)0.64%$1 MNov 16, 2026
15DG Capital Management, LLC480,166+16,770 (+3.62%)0.58%$1 MNov 12, 2026
16Geode Capital Management, LLC471,555+90,380 (+23.71%)0.57%$1 MNov 6, 2026
17Renaissance Technologies LLC446,691-190,926 (-29.94%)0.54%$1 MNov 12, 2026
18Squarepoint Ops LLC348,123New0.42%$1 MNov 9, 2026
19Ikarian Capital, LLC303,5550 (0.00%)0.37%$0 MNov 16, 2026
20Vanguard Fiduciary Trust Co301,330+110,520 (+57.92%)0.37%$0 MNov 13, 2026
21BlackRock, Inc.284,704-705 (-0.25%)0.35%$0 MNov 13, 2026
22Boothbay Fund Management, LLC284,3300 (0.00%)0.35%$0 MNov 16, 2026
23Susquehanna International Group, LLP256,771+235,560 (+1110.56%)0.31%$0 MNov 16, 2026
24Tudor Investment Corp Et Al243,383-76,717 (-23.97%)0.30%$0 MNov 16, 2026
25State Street Corp198,060+24,000 (+13.79%)0.24%$0 MNov 12, 2026
Show all 66: investors 26 to 66
Institutional investors 26 to 66 in Equillium, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Acuta Capital Partners, LLC183,000New0.22%$0 MNov 16, 2026
27Two Sigma Investments, LP141,482-65,371 (-31.60%)0.17%$0 MNov 16, 2026
28Integrated Quantitative Investments LLC126,010New0.15%$0 MNov 13, 2026
29Northern Trust Corp111,354+39,795 (+55.61%)0.14%$0 MNov 16, 2026
30Cantor Fitzgerald, L. P.109,062-109,062 (-50.00%)0.13%$0 MNov 16, 2026
31Soleus Capital Management, L.P.90,0000 (0.00%)0.11%$0 MNov 16, 2026
32Quadrature Capital Ltd76,322+47,667 (+166.35%)0.09%$0 MNov 13, 2026
33American Century Companies Inc75,411+49,516 (+191.22%)0.09%$0 MNov 12, 2026
34China Universal Asset Management Co., Ltd.64,000+39,000 (+156.00%)0.08%$0 MOct 28, 2026
35Jane Street Group, LLC57,366-37,848 (-39.75%)0.07%$0 MNov 12, 2026
36Invesco Ltd.53,227+16,936 (+46.67%)0.06%$0 MNov 12, 2026
37AlphaCore Capital LLC52,3450 (0.00%)0.06%$0 MNov 4, 2026
38XTX Topco Ltd44,883+5,620 (+14.31%)0.05%$0 MNov 16, 2026
39UBS Group AG38,241+15,309 (+66.76%)0.05%$0 MNov 10, 2026
40Royal Bank Of Canada37,197New0.05%$0 MNov 16, 2026
41Virtu Financial LLC36,100New0.04%$0 MNov 17, 2026
42Barclays PLC35,0000 (0.00%)0.04%$0 MNov 6, 2026
43Jefferies Financial Group Inc.34,1000 (0.00%)0.04%$0 MNov 5, 2026
44Schonfeld Strategic Advisors LLC33,437New0.04%$0 MNov 16, 2026
45High Net Worth Advisory Group LLC33,230-270 (-0.81%)0.04%$0 MOct 26, 2026
46Corient Private Wealth LP31,936New0.04%$0 MNov 16, 2026
47Qube Research & Technologies Ltd25,695New0.03%$0 MNov 13, 2026
48Millennium Management LLC20,819-22,019 (-51.40%)0.03%$0 MNov 16, 2026
49Vanguard Global Advisers, LLC20,044+14,218 (+244.04%)0.02%$0 MNov 13, 2026
50Hudson Bay Capital Management LP18,260New0.02%$0 MNov 13, 2026
51Gsa Capital Partners LLP17,277New0.02%$0 MNov 16, 2026
52Chung Wu Investment Group, LLC16,5000 (0.00%)0.02%$0 MNov 3, 2026
53Focus Partners Wealth16,013+3,000 (+23.05%)0.02%$0 MNov 12, 2026
54Morgan Stanley15,842-14,045 (-46.99%)0.02%$0 MNov 13, 2026
55Coastal Bridge Advisors, LLC15,0000 (0.00%)0.02%$0 MNov 18, 2026
56Apollon Wealth Management, LLC13,8750 (0.00%)0.02%$0 MOct 23, 2026
57Raymond James Financial Inc13,500-61,760 (-82.06%)0.02%$0 MNov 12, 2026
58Spark Investment Management LLC13,200New0.02%$0 MNov 13, 2026
59Legato Capital Management LLC13,137New0.02%$0 MNov 10, 2026
60Catalyst Funds Management Pty Ltd10,442New0.01%$0 MNov 12, 2026
61Group One Trading LLC2,2380 (0.00%)0.00%$0 MNov 10, 2026
62Wells Fargo & Company/mn1,0000 (0.00%)0.00%$0 MNov 16, 2026
63Jones Financial Companies Lllp5000 (0.00%)0.00%$0 MNov 13, 2026
64SBI Securities Co., Ltd.58-10 (-14.71%)0.00%$0 MOct 22, 2026
65Caitong International Asset Management Co., Ltd48-186 (-79.49%)0.00%$0 MOct 29, 2026
66Citigroup Inc13-32,682 (-99.96%)0.00%$0 MNov 4, 2026

Mutual funds holding Equillium, Inc.#

16 funds hold shares worth $19 M (about 7.2% of the company). Since their previous reports 9 added shares and 1 sold, buying $2 M net.
Mutual funds holding Equillium, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.3.63 M$12 M4.4%1.7%+8.3%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.40 M$4 M1.7%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.344,489$1 M0.42%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC164,610$0 M0.20%<0.01%+0.1%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors147,697$0 M0.18%0.03%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC54,720$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC47,465$0 M0.06%<0.01%+10%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC36,683$0 M0.04%<0.01%+15%May 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC31,335$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.24,987$0 M0.03%<0.01%+75%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.22,500$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,860$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust10,623$0 M0.01%<0.01%newMay 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP7,665$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP7,668$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.5,565$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Equillium, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$2.4 M
18 sales, 3 insiders
Net, 12 months
-$2.4 M
open market only
Insiders on file
8
since
-$766 K$0Jul 2024: bought $0 (0 trades), sold $9 K (1 trades)Jul 24Sep 2024: bought $0 (0 trades), sold $41 K (2 trades)Oct 2024: bought $0 (0 trades), sold $23 K (3 trades)OctNov 2024: bought $0 (0 trades), sold $7 K (1 trades)Jan 2025: bought $0 (0 trades), sold $7 K (1 trades)Jan 25Nov 2025: bought $0 (0 trades), sold $8 K (2 trades)Dec 2025: bought $0 (0 trades), sold $197 K (3 trades)DecJan 2026: bought $0 (0 trades), sold $8 K (1 trades)Feb 2026: bought $0 (0 trades), sold $328 K (2 trades)FebMar 2026: bought $0 (0 trades), sold $663 K (2 trades)May 2026: bought $0 (0 trades), sold $459 K (5 trades)MayJun 2026: bought $0 (0 trades), sold $766 K (3 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Equillium, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Christine ZedelmayerSr. Vice President and COOOption exercise10b5-1 plan+14,584$0.790$12 K77,170Form 4
filed Stephen ConnellyPresident and CSOSell-30,975$2.940$91 K762,025Form 4
filed Christine ZedelmayerSr. Vice President and COOSell10b5-1 plan-14,584$2.930$43 K62,586Form 4
filed Stephen ConnellyPresident and CSOSell-200,000$3.160$632 K793,000Form 4
filed Penny TomPrincipal Accounting OfficerOption exercise10b5-1 plan+65,000$0.790$51 K65,000Form 4
filed Penny TomPrincipal Accounting OfficerSell10b5-1 plan-65,000$2.950$192 K0Form 4
filed Christine ZedelmayerSr. Vice President and COOOption exercise10b5-1 plan+7,292$0.730$5 K69,878Form 4
filed Christine ZedelmayerSr. Vice President and COOOption exercise10b5-1 plan+48,512$0.770$37 K118,390Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Equillium, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.9 M
9.6% of shares · 9.52 days to cover
Buybacks, Q4 2023
$0M
Q4 2023
Shares sold short, last 24 reportsAll stocks →
Equillium, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2023Q4 2023$0M

Trading halts

  • 2025-08-11 14:13 UTC, code LUDP, resumed 14:18 UTC
  • 2025-08-11 13:33 UTC, code LUDP, resumed 13:38 UTC
  • 2025-08-01 19:14 UTC, code LUDP, resumed 19:19 UTC
  • 2025-08-01 19:06 UTC, code LUDP, resumed 19:11 UTC

Fails to deliver

  • : 3,160 shares at $1.25
  • : 3,573 shares at $1.42
  • : 49,654 shares at $1.45
  • : 4,158 shares at $1.89
  • : 401 shares at $2.42

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Equillium, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 27, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.6×Price to book 3.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-22.2%Free cash flow is -22.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.39 vs -0.23Diluted EPS -0.39 in fiscal 2025 against -0.23 the year before (report's currency).
    • ✓Net income higher than five years earlier-$22 M-$22 M in fiscal 2025 against -$30 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-94.0%-94.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities10.6×Current ratio 10.59 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year62.1%Diluted shares up 62.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Equillium, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Equillium, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue—413616————
Research and development133737382619184.9r
General and administrative1112141711109.13.7r
Operating expenses244951783830278.6r
Operating income−24−8.3−15−62−38−30−27−8.6r
Interest and finance income0.81.42.30.40.10.51.40.3r
Interest expense and finance costs——0.51.11.11.10.32.6r
Other non-operating income (expense)——1.8−0.4−1.3−0.31.1−4.6r
Income before tax−22−7.7−13−62−39−30−26−13
Income tax00.40.6000——
Net income including minority interests−22−8.1−13−62−39−30−26−13r
Net income attributable to shareholders−22−8.1−13−62−39−30−26−13r
Earnings per share, basic-0.39-0.23-0.38-1.85-1.36-1.46-1.47-1.09
Earnings per share, diluted-0.39-0.23-0.38-1.85-1.36-1.46-1.47-1.09
Shares, weighted average (basic)5735353429———
Shares, weighted average (diluted)5735353429201712
Balance sheet
Cash and cash equivalents3018235950241329r
Short-term investments—4.5181230584037r
Receivables—03.72.80———
Other current assets0.20.40.20.0r2.73.02.31.2r
Current assets3125497783855567r
Property, plant and equipment0.20.30.30.40.20.20.10.1r
Right-of-use (leased) assets0.70.40.81.21.6———
Total assets3226517885855667r
Accounts payable0.82.74.74.01.22.81.91.1r
Debt due within a year———5.71.41.7——
Current liabilities2.96.428328.97.23.92.0r
Long-term debt———3.28.88.39.7—
Lease liabilities (non-current)0.40.20.40.81.2———
Non-current liabilities———————0.2
Total liabilities3.36.528461916142.2r
Retained earnings−216−194−186−172−110−71−41−16r
Shareholders' equity2919233267704265r
Total liabilities and equity3226517885855667r
Shares outstanding6136353429251717
Cash-flow statement
Depreciation and amortization———0.10.10.00.00.0r
Share-based compensation2.33.84.04.84.43.82.30.4r
Cash from operating activities−23−19−22−8.7−32−25−23−7.5r
Capital expenditure−0.0−0.1−0.1−0.3−0.1−0.2−0.1−0.0r
Cash from investing activities4.514−4.81927−19−2.2−37r
Shares issued——————−0.2—
Shares bought back——−0.3—————
Cash from financing activities300.2−9.2−1.231549.866r
Change in cash12−5.1−368.72611−1521r
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Equillium, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Equillium, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Equillium, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$4.3 M
Bruce D. Steel
Other top executives, average
$2.4 M
the CEO earned 1.8× this
$100 invested is now
$146
Equillium, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Bruce D. Steel$4.3 M$4.5 M$2.4 M$146
2024Bruce D. Steel$684 K$754 K$513 K$71
2023Bruce D. Steel$1.3 M$1.0 M$806 K$68

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Equillium, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Auditor changed 2 · Directors and officers 3 · Material agreement 3 · Unregistered share sale 3 · Shareholder vote 2 · Results announced 11

Equillium, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Unregistered share sale8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Auditor changed8-K/A
Auditor changedDirectors and officers8-K
Material agreementUnregistered share sale8-K
Material agreementResults announced8-K
Delisting notice8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

How Equillium, Inc. compares in Biotechnology

  • Market cap$103 M · higher than 36% of 726
  • Revenue growth13.9% · higher than 56% of 438
  • Price / book3.6× · lower than 41% of 534
  • FCF yield-22.2% · higher than 42% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Equillium, Inc.🇺🇸$103 M——+13.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 27, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Equillium, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Equillium, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Equillium, Inc.? Suggest a correction